ICUI at a glance
ICU MEDICAL INC/DE (ICUI, SEC CIK 883984) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ICU MEDICAL INC/DE (ICUI) reported revenue of $2.2 billion (down 6.3% from FY2024) and net income of $732,000. Diluted EPS was $0.03.
- As of June 30, 2026, 30 institutional investment managers tracked by SignalX reported holding ICU MEDICAL INC/DE (ICUI) shares worth $1.9 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Sanzone Virginia Ruth on September 3, 2026 of 724 shares at $169.53 per share.
- In the last 90 days, ICUI insiders reported 0 open-market purchases ($0) and 13 open-market sales ($6.6M) on Form 4, a net sale of $6.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.2B
- −6.3% vs prior year
- Insiders · 90 days
- 0 buys · 13 sells
- Net −$6.6M
- 13F holders
- 30 funds
- $1.9B · +0 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development, manufacturing, and sales of innovative medical products for infusion therapy, vascular access, and vital care applications worldwide
- New strategic joint venture formed in April 2025, selling 60% controlling interest in IV Solutions business to Otsuka Pharmaceutical Factory America
- Introduction of Plum Duo™ and Plum Solo™ precision infusion pumps with FDA clearance in April 2025, featuring ±3% delivery accuracy and dual channel medication delivery
- Employees and geographic expansion details not disclosed; strongest product recognition includes Plum 360™ winning Best in KLAS awards for eight years, including 2025
- Noteworthy separation of IV Solutions in a joint venture while retaining 40% interest, coupled with continuing commercial agreements for sales and distribution post-divestiture
Risk Factors
- Regulatory risk Italy Medical Device Payback law IMDP liability settled for $2.5M with $3.8M reserve release in 2025
- Macroeconomic exposure $85M-$100M capital expenditures planned across Costa Rica, Europe, Mexico, and U.S. manufacturing in 2026
- Operational risk integration and restructuring expenses post-Smiths Medical acquisition estimated at $60M-$80M in 2026
- Competitive risk infusion pump market affected by expansion investment; no direct competitor named but global production increased
- Financial risk $1.25B credit facilities with potential accelerated maturity 91 days before Term Loan B due in 2029
Management Discussion & Analysis
- Foreign currency exposure partially hedged, not fully covering forecasted revenues and expenses
- Potential increased risk from unhedged currency fluctuations impacting financial results
- Additional hedging contracts could limit losses but also pose counter-party risk and financial harm
- Current hedging efforts may not fully offset adverse currency exchange rate impacts
- Currency risks could materially negatively affect financial condition or results of operations
AI summary of the ICUI 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- No profitability or margin percentages disclosed in supplied text
- $18.9M tariff refunds recognized in cost of goods sold during Q2 2026
- $0.7M related tariff-refund interest income recognized in interest expense, net
- $211.2M IV Solutions transaction proceeds, including $200.0M Term Loan A repayment in Q2 2025
Risk Factors
- No Risk Factors section provided in the excerpt
- No disclosed new or changed risks identifiable from the provided text
- Credit Agreement restrictions limit stock repurchases under the $100 million authorization
- CFO Rule 10b5-1 plan covers 24,535 securities through June 1, 2027
- General Counsel Rule 10b5-1 plan covers 4,856 securities through June 4, 2027
AI summary of the ICUI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced by ICU Medical on August 6, 2026
- Detailed operating results and financial metrics contained in furnished Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $551.7M, up 1% YoY; organic revenue increased 6% excluding IV Solutions divestiture and foreign currency
- Infusion Systems revenue $189.0M, up 13%; Consumables revenue $289.3M, up 6%
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Stockholders approved simple-majority voting, lowering thresholds for future corporate actions
- Special-meeting rights granted to holders of at least 25% of voting power
Item 5.07: Submission of Matters to a Vote of Security Holders
- All seven director nominees elected, with votes for ranging from 21,830,140 to 21,951,116
- Deloitte & Touche LLP appointment ratified for fiscal year ending December 31, 2026, with 23,862,197 votes for
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 financial results announced by ICU Medical on May 7, 2026
- Detailed results and management commentary furnished in Exhibit 99.1
AI summaries of ICUI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ICUI
Don't miss the next ICUI filing
- Alerts as it files. A push when ICUI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ICUI, by share count.
- Ask anything. An AI agent that reads every ICUI filing and answers with sources.
ICUI alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sanzone Virginia Ruth | Sell | Sep 3, 2026 | 724 | $169.53 |
| Sanzone Virginia Ruth | Sell | Sep 3, 2026 | 2,202 | $167.67 |
| Sanzone Virginia Ruth | Sell | Sep 3, 2026 | 692 | $171.51 |
| Sanzone Virginia Ruth | Sell | Sep 3, 2026 | 1,238 | $168.44 |
| Bonnell Brian Michael | Sell | Sep 1, 2026 | 6,381 | $175.00 |
| Bonnell Brian Michael | Sell | Aug 31, 2026 | 1,712 | $171.05 |
| Bonnell Brian Michael | Sell | Aug 31, 2026 | 1,914 | $172.12 |
| Bonnell Brian Michael | Sell | Aug 31, 2026 | 1,113 | $173.91 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.4B | $2.2B |
| Gross Profit | - | $824.8M | $822.0M |
| Operating Income | - | $43.0M | $42.8M |
| Net Income | - | -$117.7M | $732K |
| Gross Margin | - | 34.6% | 36.8% |
| Op. Margin | - | 1.8% | 1.9% |
| Net Margin | - | -4.9% | 0.0% |
| Balance Sheet | |||
| Total Assets | $4.4B | $4.2B | $4.1B |
| Equity | $2.1B | $2.0B | $2.1B |
| ROE | - | -6.0% | 0.0% |
| Per Share | |||
| EPS | - | $-4.83 | $0.03 |
| Cash Flow | |||
| Operating CF | - | $204.0M | $179.8M |
| CapEx | - | $79.4M | $88.0M |
Source: XBRL data in ICU MEDICAL INC/DE (ICUI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ICUI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 30 | $1.86B |
| Q1 2026 | 30 | $1.57B |
| Q4 2025 | 29 | $1.75B |
| Q3 2025 | 29 | $1.66B |
| Q2 2025 | 30 | $1.66B |
| Q1 2025 | 29 | $1.29B |
| Q4 2024 | 24 | $1.18B |
| Q3 2024 | 21 | $760.5M |
- Citadel Advisors LLC+202.9K (+61%)
- BlackRock+145.1K (+4%)
- Goldman Sachs Group+94.7K (+29%)
- Ameriprise Financial+83.8K (+14%)
- Dimensional Fund Advisors+69.7K (+7%)
- Morgan Stanley−154.3K (-29%)
- Millennium Management−61.0K (-90%)
- FMR LLC (Fidelity)−29.7K (-10%)
- JPMorgan Chase & Co−27.3K (-6%)
- Prudential Financial−10.8K (-29%)
- D.E. Shaw & Co+20.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 222 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ICUI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | May 22, 2026 | - | - | |
| 8-K | May 18, 2026 | - | Analysis | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| SC 13G | Apr 30, 2026 | - | - | |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Mar 26, 2026 | - | - | - |
| 4 | Mar 16, 2026 | - | - | - |
| 4 | Mar 16, 2026 | - | - | - |
| 4 | Mar 16, 2026 | - | - | - |
| 4 | Mar 16, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
ICUI SEC filings: frequently asked questions
Are ICUI insiders buying or selling?
In the last 90 days, ICU MEDICAL INC/DE (ICUI) officers, directors and 10% owners reported no open-market purchases and 13 open-market sales worth $6.6 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ICUI stock?
As of June 30, 2026, the largest ICU MEDICAL INC/DE (ICUI) holders among the 13F filers tracked by SignalX were BlackRock ($550.3 million), Vanguard Portfolio Management LLC ($215.6 million), Vanguard Capital Management LLC ($164.7 million), Dimensional Fund Advisors ($154.4 million), State Street Corp ($150.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ICUI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ICU MEDICAL INC/DE (ICUI) reported revenue of $2.2 billion (down 6.3% from FY2024) and net income of $732,000. Diluted EPS was $0.03. The figures come from the XBRL data in the 10-K.
What are the main risks in ICUI's latest 10-K?
In the 10-K filed February 19, 2026, ICU MEDICAL INC/DE (ICUI) flagged: Regulatory risk Italy Medical Device Payback law IMDP liability settled for $2.5M with $3.8M reserve release in 2025. Macroeconomic exposure $85M-$100M capital expenditures planned across Costa Rica, Europe, Mexico, and U.S. manufacturing in 2026. (AI summary of the Risk Factors section.)
What did ICUI report in its latest 8-K?
ICU MEDICAL INC/DE (ICUI) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced by ICU Medical on August 6, 2026.
What are the latest ICUI SEC filings?
ICU MEDICAL INC/DE (ICUI) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on September 3, 2026.
What is ICUI's SEC CIK number?
ICU MEDICAL INC/DE (ICUI)'s SEC Central Index Key (CIK) is 883984. EDGAR lists every ICUI filing under that number.
Ask anything about ICUI
The research agent reads ICUI's filings, financials, insider trades and 13F holders, then answers with sources.